Stock 688575 SHENZHEN YHLO BIOTECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shenzhen YHLO Biotech Co., Ltd.

Equities

688575

CNE100005204

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
24.29 CNY +3.05% Intraday chart for Shenzhen YHLO Biotech Co., Ltd. +5.47% +6.21%
May. 17 Certain A Shares of Shenzhen YHLO Biotech Co., Ltd. are subject to a Lock-Up Agreement Ending on 17-MAY-2024. CI
Apr. 19 Shenzhen YHLO Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The firm trades with high earnings multiples: 28.71 times its 2024 earnings per share.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
SHENZHEN YHLO BIOTECH CO., LTD. Stock Shenzhen YHLO Biotech Co., Ltd.
+6.21% 1.91B -
SHOCKWAVE MEDICAL, INC. Stock Shockwave Medical, Inc.
+75.69% 12.57B
B-
PENUMBRA, INC. Stock Penumbra, Inc.
-24.68% 7.34B
C+
MASIMO CORPORATION Stock Masimo Corporation
+6.22% 6.61B
C-
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. Stock Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
+12.58% 5.39B
D+
APT MEDICAL INC. Stock APT Medical Inc.
+26.90% 4.53B -
ASAHI INTECC CO., LTD. Stock Asahi Intecc Co., Ltd.
-21.14% 3.91B
B-
INARI MEDICAL, INC. Stock Inari Medical, Inc.
-22.99% 2.91B
C
NOVOCURE LIMITED Stock NovoCure Limited
+47.42% 2.37B
C-
SKAN GROUP AG Stock SKAN Group AG
-0.37% 2B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 688575 Stock
  4. Ratings Shenzhen YHLO Biotech Co., Ltd.